Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up to $133.66

Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $133.66, but opened at $141.00. Neurocrine Biosciences shares last traded at $141.02, with a volume of 432,096 shares changing hands.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on NBIX shares. Citigroup cut their price objective on Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating for the company in a research report on Thursday, February 8th. HC Wainwright reiterated a “buy” rating and set a $150.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday. StockNews.com upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Oppenheimer reiterated an “outperform” rating and set a $200.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, April 10th. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $142.38.

Neurocrine Biosciences Stock Down 0.8 %

The stock has a market capitalization of $13.83 billion, a price-to-earnings ratio of 57.43 and a beta of 0.25. The company’s 50-day simple moving average is $136.48 and its 200 day simple moving average is $127.62.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.13 by $0.31. The firm had revenue of $515.20 million for the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The business’s quarterly revenue was up 25.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.88 earnings per share. On average, equities analysts expect that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 5,000 shares of the stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total transaction of $725,300.00. Following the transaction, the insider now directly owns 7,507 shares of the company’s stock, valued at $1,088,965.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 5,000 shares of the company’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $145.06, for a total transaction of $725,300.00. Following the completion of the sale, the insider now directly owns 7,507 shares in the company, valued at $1,088,965.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard F. Pops sold 15,000 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the sale, the director now owns 29,512 shares of the company’s stock, valued at $3,909,454.64. The disclosure for this sale can be found here. Insiders have sold 186,994 shares of company stock valued at $25,806,409 over the last three months. 4.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of hedge funds have recently bought and sold shares of the company. CWM LLC lifted its stake in shares of Neurocrine Biosciences by 47.9% in the third quarter. CWM LLC now owns 2,049 shares of the company’s stock valued at $231,000 after buying an additional 664 shares during the period. AE Wealth Management LLC bought a new stake in shares of Neurocrine Biosciences in the third quarter valued at about $521,000. SG Americas Securities LLC bought a new stake in shares of Neurocrine Biosciences in the third quarter valued at about $2,751,000. Avior Wealth Management LLC lifted its stake in shares of Neurocrine Biosciences by 74.4% in the third quarter. Avior Wealth Management LLC now owns 4,509 shares of the company’s stock valued at $507,000 after buying an additional 1,924 shares during the period. Finally, Asset Management One Co. Ltd. lifted its stake in shares of Neurocrine Biosciences by 0.5% in the third quarter. Asset Management One Co. Ltd. now owns 38,662 shares of the company’s stock valued at $4,349,000 after buying an additional 207 shares during the period. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.